EOS Imaging (Formerly Known as biospace med) Announces the Registration of its "Document De Base" by the Autorite Des Marches Financiers, a Key Milestone Towards an Initial Public Offering on the Regulated Market of NYSE Euronext in Paris
Published: Jan 23, 2012
EOS imaging designs, develops and markets EOS, a medical imaging system revolutionising the treatment chain of the main osteoarticular diseases (hips, knees, back) and related orthopedic surgery. Based upon the work of Physics Nobel Prize Winner Georges Charpak, the EOS system is the first imaging solution capable of producing, in one step, a 2D and 3D image of the uprightskeleton with a very low radiation dose. EOS 2D/3D images are produced in the patient's natural functional position, raising the accuracy of diagnosis, surgery and osteoarticular pathological follow-up.
The EOS imaging group has obtained marketing authorisations in 30 countries including the United States (FDA), Canada, Australia and the European Union (CE). With a workforce of 57 employees, including an R&D team of 21 engineers, the EOS imaging group posted sales of €4.8 million in 2010.
EOS imaging aspires to turn into the key player in orthopeadic medical imaging and aims more specifically at:
• increasing international marketing activities on existing markets and to develop in new geographical areas;
• expanding the offer of services and innovative applications to address specific clinical requirements; • pursuing the expansion of technological innovations based on the EOS platform.
Registration of the document de base is the first step towards EOS imaging's initial public offering on the regulated market of NYSE Euronext in Paris. The IPO should take place in 2012, subject to market conditions and to the AMF approval of the IPO prospectus.
The Initial Public Offering (IPO) of EOS imaging aims at allowing the company to pursue its development until profitability.
On request, EOS imaging's document de base is available free of charge from EOS imaging (10, rue Mercœur - 75011 PARIS - France) and from the websites of EOS imaging (www.eos-imaging.com) and Autorité des marchés financiers (www.amf france.org). EOS imaging wishes to draw investor attention to Section 4, "Risk Factors" and more specifically to section 4.4.2 (Liquidity risk – Future capital needs and additional financing) in the document de base registered with the AMF
About EOS imaging:
The EOS imaging group designs, develops and markets EOS®, a revolutionary and patented medical imaging system, based ontechnology that enabled George Charpak to win the Nobel Prize for Physics. The Group has obtained authorisation to market the system in 30 countries, including the United States (FDA), Canada, Australia and the European Union (EC). Thanks to an installed base of 42 sites and more than 150,000 imaging sessions, EOS® benefits from worldwide recognition and established credibility within the medical community. The Group currently employs 57 people including an R&D team of 21 engineers and recorded consolidated revenue of €4.8 million in 2010. The Group's head office is based in Paris, with a subsidiary in the United States at Cambridge, Massachusetts, as well as offices in Montreal (Canada) and Germany.
Further information about EOS imaging can be found at the following site: www.eos-imaging.com
Tel.: +33 (0) 1 55 25 61 24
Financial communication and investor relations
Sophie Boulila / Pierre Laurent
Tel.: +33(0)1 44 71 94 91 – email@example.com
Caroline Carmagnol / Anne-Sophie Cosquéric
Tel : +33 (0) 1 42 68 86 43 / +33 (0) 6 64 18 99 59
firstname.lastname@example.org / email@example.com